One of quantum computing’s central problems is that errors happen and you often don’t know it until you measure — by which point the quantum state is gone. A new method published this week can detect quantum information loss more than 100 times faster than previous approaches, tracking changes in near real time.

That’s not a fix for decoherence. But it’s a significantly better diagnostic tool, which matters for the engineering cycle. You can’t fix what you can’t see.

One week of intensive meditation practice: improved brain efficiency, boosted immune signaling, increased natural pain relief chemicals.

Seven days. Not years of practice. The brain responds faster than most people assume.

Whether this persists or fades without continued practice isn’t answered here. But “measurable changes in a week” is a more accessible finding than the usual “long-term meditators show differences.”

Southwest China. Discovery of animal groups that weren’t supposed to exist yet — millions of years earlier than the timeline said was possible.

Every time paleontology does this it’s a little disorienting. The story of life on Earth keeps getting older, stranger, and more front-loaded than the previous model assumed.

“Lost world” is a press release word but the underlying finding is genuinely significant. The Cambrian explosion might be less of an explosion and more of a long fuse.

Called FTL1. In aging mice, higher levels of this protein weakened connections between brain cells and caused memory decline. Reducing it reversed some of that.

Mice aren’t humans. But every time something like this shows up, it’s one more piece of the puzzle of why the brain degrades. The idea that aging might be modifiable rather than fixed is no longer fringe science.

Filed under: things I hope pan out before I need them.

Researchers have demonstrated a working quantum battery prototype that uses quantum mechanical effects to charge faster and more efficiently than conventional batteries at small scales. The results, published this week, show that quantum entanglement and superposition can be practically harnessed in an energy storage context — something that has been theorized for years but not convincingly demonstrated.

The “sort of” caveat: the prototype operates under highly controlled laboratory conditions and at scales far removed from anything you’d put in a phone or a car. The gap between proof-of-concept and consumer product is wide and filled with engineering problems that quantum elegance doesn’t automatically solve.

Oregon State. Captured the actual chemical interactions driving Alzheimer’s — copper ions triggering harmful protein behavior — as they happened.

Not a model. Not a simulation. Actual observation of the process.

Seeing something clearly is not the same as being able to stop it. But you can’t target what you can’t see. This is the kind of finding that makes treatment research more precise.

Astrocytes — cells that were thought to just support neurons — apparently play a key role in controlling appetite. They’re the ones sending the “stop eating” signal.

The same cells also turned up recently in research on fear memory and chronic pain. Astrocytes are having a moment. Turns out “support cells” were doing a lot more than supporting.

New research confirms that bottled water contains significantly more microscopic plastic particles than earlier studies estimated. The discrepancy comes from improved detection methods — earlier analyses couldn’t identify the smallest nanoplastic particles, which turn out to be the most numerous.

How much more? The new counts run into the hundreds of thousands of particles per liter, depending on the brand and bottle type. Previous estimates were in the thousands.

The health implications remain contested. Research on what nanoplastics do inside the human body at these concentrations is ongoing, and there is no scientific consensus yet on the threshold at which harm becomes measurable. What is clear: the particles are there, they are abundant, and they are small enough to cross biological membranes.

The U.S. Government Accountability Office has released its second annual science and technology horizon scan, and the selection is pointed: neural implants for human augmentation, general purpose robotics, and orbital debris remediation. Three technologies that share almost nothing on the surface — and almost everything underneath.

The report (GAO-26-108079) uses a STEER framework — Social, Technological, Environmental, Economic, Regulatory — to map not just what these technologies do but what conditions need to exist for them to matter. That framing is more honest than most tech forecasts. It treats innovation as a systemic outcome, not a product release event.

H5N1 has been circulating in birds for years. The reason it is getting more attention now is specific and worth understanding clearly.

The virus crossed into cattle in the US in 2024 — an unexpected host jump that expanded the pool of potential human exposure significantly. Dairy farm workers have tested positive in multiple states. Most cases involved mild illness: eye irritation, respiratory symptoms, rapid recovery. No sustained human-to-human transmission has been documented. That last sentence is the most important one in any bird flu discussion, and it remains true as of now.

2025 was confirmed as the hottest year in recorded human history, continuing a streak that has now run for over a decade. The science is not the contested part anymore. What deserves more attention is the gap between what is being done and what the models say is necessary.

Global renewable energy deployment is genuinely accelerating. Solar installation in particular has beaten nearly every projection made ten years ago — costs have fallen faster and adoption has spread wider than analysts expected. This is good news and it is real. The problem is that it is happening alongside continued fossil fuel use rather than replacing it at the rate required to hit agreed temperature targets.

Ozempic and Wegovy get talked about as weight loss drugs. That framing is increasingly inadequate for what GLP-1 receptor agonists appear to be doing.

The weight loss results are real and significant — patients losing 15 to 20% of body weight in clinical trials far exceeds what any previous pharmaceutical intervention achieved. But the downstream effects are where the story gets more interesting. Large-scale trials have shown meaningful reductions in cardiovascular events — heart attacks and strokes — in patients taking semaglutide, independent of weight loss effects. Separate research is showing promising signals in addiction behavior: patients reporting reduced cravings not just for food but for alcohol, nicotine, and other substances.